(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-carbamic acid phenyl ester | 1256821-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-carbamic acid phenyl ester
• 英文别名: Phenyl N-[6-(1-piperidinyl)-3-pyridinyl]carbamate；phenyl N-(6-piperidin-1-ylpyridin-3-yl)carbamate
• CAS: 1256821-21-2
• 化学式: C₁₇H₁₉N₃O₂
• 分子量: 297.357
• InChiKey: KPZRERVPNCPXJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  哌啶 在 吡啶 、 铁粉 、 potassium carbonate 、 氯化铵 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 15.0h， 生成 (3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-carbamic acid phenyl ester
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS
  [FR] COMPOSITIONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES POUR PRÉVENIR OU TRAITER UNE MALADIE OU UN TROUBLE PROVOQUÉ PAR OU ASSOCIÉ À UN OU PLUSIEURS CODONS DE TERMINAISON PRÉMATURÉS

  摘要：

  本公开涉及式I的化合物或其药学上可接受的盐，其中A为式II，X1为线性或支链C1-6烷基，C3-6环烷基，C6-10芳基，5-10成员杂芳基，4-8成员杂环烷基，其中X1未取代或取代有卤素，线性或支链C1-6烷基，线性或支链C1-6杂烷基，CF3，CHF2，CMeF2，-O-CHF2，-O-(CH2)2-OMe，OCF3，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-OC(O)-C1-4烷基氨基，-C(O)O-C1-6烷基，-COOH，-CHO，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-6烷氧基或Cue烷基羟基；或X1与X4共同形成未取代或取代有卤素，线性或支链C1-6烷基，CF3，CHF2，CMeF2，-O-(CH2)2-OMe，OCF3，OCHF2，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-C(O)O-C1-6烷基，-COOH，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-4烷基羟基或C1-4烷氧基的4-8成员杂环烷基；X2为氢，C3-6环烷基，C6-10芳基，5-10成员杂芳基，4-8成员杂环烷基，其中X2未取代或取代有线性或支链Cue烷基，-C1-4烷氧基，NH2，NMe2，卤素，CF3，CHF2，CMeF2，-O-(CH2)2-OMe，OCF3，OCHF2，CM烷基羟基，X3为-NH-，-O-；X4为-NH-，-CH2-；L1为共价键，C1-6烷基，未取代或取代有C1-4烷基，卤素；L2为共价键，Cue烷基，未取代或取代有CM烷基，卤素；L3为共价键，-O-，-C1-4烷氧基或C1-6烷基，未取代或取代有C1-4烷基，卤素，用于单一疗法或与氨基糖苷类药物或其药学上可接受的盐联合疗法预防和治疗由一个或多个过早终止密码子引起或相关的疾病或障碍。

  公开号：

  WO2022200857A1

文献信息

• [EN] HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE DE TYPE DIAMINE URÉE SPIROCYCLIQUE SUBSTITUÉE PAR UN GROUPE HÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010141817A1

  公开（公告）日：2010-12-09

  Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的螺环二胺脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制药组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和条件的方法，如焦虑、疼痛、炎症、睡眠紊乱、进食紊乱、能量代谢紊乱和运动紊乱（例如多发性硬化）。
• Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines
  申请人：NEUROGEN CORPORATION

  公开号：US20030036652A1

  公开（公告）日：2003-02-20

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  提供了能够调节NPY5受体活性的替代螺环[异苯并呋喃-1,4′-哌啶]-3-酮和3H-螺环异苯并呋喃-1,4′-哌啶。这些化合物可用于在体内或体外调节NPY5受体的配体结合，并且在治疗各种疾病（例如，肥胖或暴食症等进食障碍、精神障碍、糖尿病和高血压等心血管疾病）方面对人类、驯养的伴侣动物和家畜动物特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测NPY5受体的这些化合物的方法。
• Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
  申请人：Bakthavatchalam Rajagopal

  公开号：US20050033048A1

  公开（公告）日：2005-02-10

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  本文提供了能够调节NPY5受体活性的取代的spiro[异苯并呋喃-1,4'-哌啶]-3-酮和3H-spiro异苯并呋喃-1,4'-哌啶。这些化合物可以用于体内或体外调节NPY5受体的配体结合，并且在人类、宠物和家畜动物的多种疾病治疗中特别有用（例如，饮食失调如肥胖症或贪食症、精神障碍、糖尿病和心血管疾病如高血压）。提供了制药组合物和治疗这些疾病的方法，以及使用这些化合物检测NPY5受体的方法。
• Spiro&lsqb;isobenzofuran-1,4′-piperidin&rsqb;-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
  申请人：Pfizer Inc.

  公开号：US06566367B2

  公开（公告）日：2003-05-20

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  本发明提供了能够调节NPY5受体活性的取代的螺[异苯并呋喃-1,4'-哌啶]-3-酮和3H-螺异苯并呋喃-1,4'-哌啶类化合物。这些化合物可用于体内或体外调节配体与NPY5受体的结合，并在治疗多种疾病（例如，饮食失调，如肥胖症或贪食症，精神障碍，糖尿病和心血管疾病，如高血压）的人类、家养伴侣动物和家畜动物中特别有用。还提供了用于治疗这些疾病的制药组合物和方法，以及用于检测NPY5受体的方法。
• Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
  申请人：De Lombaert Stéphane

  公开号：US06943199B2

  公开（公告）日：2005-09-13

  Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

  提供了能够调节NPY5受体活性的代替的spiro [异苯并呋喃-1,4'-哌啶] -3-酮和3H-spiroisobenzofuran-1,4'-哌啶。这些化合物可以用于体内或体外调节配体结合到NPY5受体，并在人类、家养伴侣动物和家畜动物的多种疾病治疗中特别有用（例如，饮食失调，如肥胖或贪食症，精神障碍、糖尿病和心血管疾病，如高血压）。提供了用于治疗这些疾病的药物组合物和方法，以及用于检测NPY5受体的这些化合物的方法。